Aurinia Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Aurinia Pharmaceuticals (AUPH) PT Raised to $11 at RBC Capital
March 20, 2019 6:29 AM EDTRBC Capital analyst Douglas Miehm raised the price target on Aurinia Pharmaceuticals (NASDAQ: AUPH) to $11.00 (from $9.00) while maintaining a Outperform rating.
no surprises out of the resultsremains on track in its Ph. III lupus nephritis trialupdated model on positive IP developments for voclosporin... MoreAurinia Pharmaceuticals (AUPH) Misses Q4 EPS by 2c
March 19, 2019 4:03 PM EDTAurinia Pharmaceuticals (NASDAQ: AUPH) reported Q4 EPS of ($0.17), $0.02 worse than the analyst estimate of ($0.15).
For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.
... More